Figure 2.
Impact of PPFs of PK origin by proactive TDM and prior biologics on CRP-based clinical remission status over time. Estimates are as follows: θpop = 0.5 ± 0.3 (p = 0.100); θcov, prior biologics = −1.2 ± 0.3 (p< 0.001); θcov, PPFs of PK origin >0 = −0.8 ± 0.3 (p = 0.008); θcov, proactive TDM = 0.8 ± 0.2 (p< 0.001); θTime = 0.004 ± 0.001 (p< 0.001). (A) Probability of CRP-based clinical remission in patients naïve to biologics. (B) Probability of CRP-based clinical remission in patients with prior biologics. The probability of CRP-based remission in the presence of proactive TDM and PPK > 0 was indistinguishable from the probability from the probability of with no TDM and PPF of PK = 0. PPF, poor prognostic factor; PK, pharmacokinetic; TDM, therapeutic drug monitoring; CRP, C-reactive protein.